Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis. Keystone, E., Genovese, M. C., Taylor, P., Zhu, B., Beattie, S. D., de Bono, S., Rooney, T., Schlichting, D. E., Macias, W. WILEY-BLACKWELL. 2013: S607

View details for Web of Science ID 000325359203414